Cart
sales@molnova.com
Repertaxin
CAS No. 266359-83-5
Repertaxin( Repertaxin | DF 1681Y )
Catalog No. M17461 CAS No. 266359-83-5
Reparixin is a potent inhibitor of both CXCL8 receptors CXCR1/2, it inhibits weakly CXCR2-mediated cell migration (IC50=100 nM), whereas it strongly blocks CXCR1-mediated chemotaxis (IC50=1 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 107 | In Stock |
|
| 5MG | 38 | In Stock |
|
| 10MG | 53 | In Stock |
|
| 25MG | 117 | In Stock |
|
| 50MG | 183 | In Stock |
|
| 100MG | 295 | In Stock |
|
| 200MG | 439 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRepertaxin
-
NoteResearch use only, not for human use.
-
Brief DescriptionReparixin is a potent inhibitor of both CXCL8 receptors CXCR1/2, it inhibits weakly CXCR2-mediated cell migration (IC50=100 nM), whereas it strongly blocks CXCR1-mediated chemotaxis (IC50=1 nM).
-
DescriptionReparixin is a potent inhibitor of both CXCL8 receptors CXCR1/2, it inhibits weakly CXCR2-mediated cell migration (IC50=100 nM), whereas it strongly blocks CXCR1-mediated chemotaxis (IC50=1 nM).
-
In Vitro——
-
In Vivo——
-
SynonymsRepertaxin | DF 1681Y
-
PathwayGPCR/G Protein
-
TargetCannabinoid Receptor
-
RecptorCXCR1| CXCR2
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number266359-83-5
-
Formula Weight283.39
-
Molecular FormulaC14H21NO3S
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 500 mg/mL; 1764.35 mM
-
SMILESCS(=O)(=O)NC(=O)[C@@H](c1ccc(CC(C)C)cc1)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Moriconi A, et al. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem. 2007 Aug 23;50(17):3984-4002.
molnova catalog
related products
-
AZD1940
AZD1940 (UNII-0J0035E9FT) is a high affinity CB(1)/CB(2) receptor agonist of the cannabinoid with oral activity. Application in the study of orofacial pain.
-
EHP-101
VCE-004.8 is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. VCE-004.8 attenuates adipogenesis and prevents diet-induced obesity.
-
LY2828360
LY2828360 is a cannabinoid (CB) receptor 2 agonist (Ki = 40.3 nM). It selectively activates CB2 over CB1 in a GTPγS binding assay (EC50s = 20.1 and >100000 nM respectively).
